#United States #Atlanta #Jazz Pharmaceuticals #Epidiolex #AES 2025

Jazz Pharmaceuticals at the American Epilepsy Society 2025 Annual Meeting

Jazz Pharmaceuticals plc recently announced the presentation of eight important abstracts at the American Epilepsy Society (AES) 2025 Annual Meeting in Atlanta, Georgia, from December 5-9, 2025. Amid this presentation, four of the abstracts were categorized as late-breaking, emphasizing significant new findings relevant to Epidiolex® (cannabidiol), particularly for patients resistant to traditional epilepsy treatments.

One of the highlights of the presentation includes interim results from the EpiCom trial, which aims to assess behavioral outcomes among individuals with tuberous sclerosis complex (TSC). This ongoing research is a Phase 3b/4 study that evaluates the effects of Epidiolex as an adjunctive treatment for seizures associated with TSC. The 6-month interim analysis showed promising results, with reductions in TAND-SQ (TSC–Associated Neuropsychiatric Disorders Self-Report Quantified Checklist) and Aberrant Behavior Checklist (ABC) scores, indicating improvements in the behavioral issues reported by caregivers and clinicians following 26 weeks of treatment.

Dr. Jessa Alexander, the head of neuroscience therapeutic area in global medical and scientific affairs at Jazz Pharmaceuticals, expressed pride in the research being shared at the AES 2025. She stated, "Our findings from the innovative EpiCom trial focused on individualized outcomes. This approach ensures we meet the priorities of patients we serve, expanding our understanding of the challenges faced by those living with rare epilepsy disorders."

In addition to the EpiCom trial results, Jazz presented further compelling data:

• - A late-breaking poster on a Phase 1 clinical study investigating the absence of pharmacokinetic interactions between Epidiolex and cenobamate when given simultaneously.
• - Noteworthy preclinical data showing a novel pharmacodynamic interaction between Epidiolex and cenobamate, enhancing effectiveness in a mouse model of seizures.
• - Two presentations detailing the real-world effectiveness of Epidiolex based on data from the U.S. Optum® Market Clarity Database. The findings suggest that Epidiolex initiation in patients with Dravet syndrome, Lennox-Gastaut syndrome, or TSC is linked to a reduction in polypharmacy and decreased healthcare resource utilization within 12 months.
• - Another analysis revealed how Epidiolex reduced not only cycling through antiseizure medications but also highlighted the efficacy of Epidiolex in minimizing seizure frequencies, showcasing significant comparative effectiveness against a placebo control group.
• - A detailed analysis of subjects from the Expanded Access Program indicated that Epidiolex treatment led to significant reductions in both convulsive and total seizure frequencies among patients with developmental and epileptic encephalopathies as well as rare epilepsy syndromes.
• - Furthermore, presented data from the Epilepsy Learning Healthcare System (ELHS) showcased real-world insights and perspectives beyond what clinical trials can provide.

Despite the complexity of medication management in epilepsy, this extensive set of findings presents significant advancements in treating rare forms of epilepsy. The evidence from the EpiCom trial and real-world studies emphasizes the importance of considering individual patient needs and experiences while conducting ongoing research. By engaging the epilepsy community, Jazz Pharmaceuticals continues to lead the way in developing effective treatments.

Jazz Pharmaceuticals remains focused on its mission to innovate and transform the lives of patients and their families, dedicating efforts to research and development in areas with few available therapeutic options. Through these studies and presentations, Jazz reinforces its commitment to making a meaningful impact in the field of epilepsy care.

All AES 2025 abstracts can be accessed here.